Form 4: RxSight Director Tamara Fountain Receives Significant Equity Grant

RxSight, Inc. Director Tamara Fountain was granted 10,752 restricted stock units (RSUs) on June 3, 2025, as part of her compensation, aligning her interests with shareholders.

Summary

• This SEC Form 4 filing reports an equity transaction by Tamara Fountain, a Director of RxSight, Inc. [RXST].
• On June 3, 2025, Ms. Fountain was granted 10,752 restricted stock units (RSUs) of RxSight, Inc. Common Stock.
• Each RSU represents a contingent right to receive one share of RxSight, Inc. Common Stock.
• The RSUs are subject to a vesting schedule where 100% will vest on the earlier of June 3, 2026 (the one-year anniversary of the grant date) or the date immediately prior to the next annual meeting of stockholders following the grant date, provided Ms. Fountain continues to serve as an Outside Director.
• Following this transaction, Tamara Fountain beneficially owns a total of 35,545 shares of RxSight, Inc. Common Stock.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is a positive step in aligning management and shareholder interests, reflecting standard compensation practices.

Positives

• The grant of 10,752 restricted stock units to Director Tamara Fountain aligns her interests with those of shareholders, as her compensation is tied to the company's future performance and stock value.
• This transaction represents a standard practice in corporate governance to incentivize long-term commitment and performance from board members.

Negatives

• No specific negative aspects are identified within this routine insider transaction filing.

Risks

• The vesting of the 10,752 restricted stock units is contingent upon Tamara Fountain's continued service as an Outside Director of RxSight, Inc. through the applicable vesting date, meaning the shares are not guaranteed if her service ceases.

Future Outlook

The future outlook indicates that Director Tamara Fountain is expected to receive 10,752 shares of RxSight, Inc. Common Stock upon the vesting of her restricted stock units, contingent on her continued service as an Outside Director until the earlier of June 3, 2026, or the date prior to the next annual meeting of stockholders.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity transaction, common across all industries for publicly traded companies. The grant of restricted stock units to a director is a standard component of executive and board compensation packages, designed to align the interests of company leadership with long-term shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units to a director is a widely accepted compensation practice within the medical technology and broader corporate sectors.
• While specific compensation amounts vary by company size, industry, and individual roles, the mechanism of using equity awards like RSUs, often with vesting conditions tied to continued service, is a global benchmark for incentivizing long-term commitment and performance from board members.
• No specific comparable companies or projects are detailed in this filing, as it focuses solely on the individual transaction.

Related Party Transactions

• The grant of restricted stock units to a director constitutes a related party transaction, as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with the long-term performance of the company, potentially leading to more shareholder-friendly decisions.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• Vesting of the 10,752 restricted stock units on the earlier of June 3, 2026, or the date immediately prior to the next annual meeting of stockholders, contingent on continued service.
• Potential future acquisition of common stock by Tamara Fountain upon the vesting and settlement of the RSUs.

Key Dates

Recommendation

Keywords

RxSight, RXST, Form 4, SEC filing, insider transaction, restricted stock units, equity grant, director compensation, Tamara Fountain